

**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025**SECTION 1. IDENTIFICATION**

Product name : XOFLUZA Tablets 80 mg

Product code : RO719-1686/F14-00

Common name(s),  
synonym(s) of the substance : XOFLUZA Film Coated Tablets 80 mg  
XOFLUZA F.C. Tablets 80 mg  
BS11564, BS11395

**Manufacturer or supplier's details**

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way  
South San Francisco, CA 94080  
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone  
In case of emergencies: : US CHEMTREC PHONE (800)-424-9300

**Recommended use of the chemical and restrictions on use**

Recommended use : Formulated pharmaceutical active substance

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

Carcinogenicity : Category 2

**GHS label elements**

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H351 Suspected of causing cancer.

Precautionary Statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Baloxavir Marboxil	1985606-14-1	16
Lactose-1-Hydrate	64044-51-5	62.2
Cellulose	9004-34-6	9.1
Croscarmellose sodium	74811-65-7	4.4
2-Pyrrolidinone, 1-ethenyl-, homopolymer	9003-39-8	4.4
sodium octadecyl fumarate	4070-80-8	1.4
Titanium oxide (TiO <sub>2</sub> )	13463-67-7	0.8
Talc (Mg <sub>3</sub> H <sub>2</sub> (SiO <sub>3</sub> ) <sub>4</sub> )	14807-96-6	0.1
non hazardous compounds	Not Assigned	1.7

**SECTION 4. FIRST AID MEASURES**

- General advice : Move out of dangerous area.  
Show this material safety data sheet to the doctor in attendance.  
Do not leave the victim unattended.
- If inhaled : If unconscious, place in recovery position and seek medical advice.  
If symptoms persist, call a physician.
- In case of skin contact : Wash off with soap and water.
- In case of eye contact : Flush eyes with water as a precaution.  
Remove contact lenses.  
Protect unharmed eye.  
Keep eye wide open while rinsing.  
If eye irritation persists, consult a specialist.
- If swallowed : Induce vomiting immediately and call a physician.  
Keep respiratory tract clear.  
Do not give milk or alcoholic beverages.  
Never give anything by mouth to an unconscious person.  
If symptoms persist, call a physician.  
Take victim immediately to hospital.

**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

- Most important symptoms and effects, both acute and delayed : Suspected of causing cancer.
- Protection of first-aiders : First Aid responders should pay attention to self-protection and use the recommended protective clothing
- Notes to physician : Treat symptomatically.

---

**SECTION 5. FIRE-FIGHTING MEASURES**

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Unsuitable extinguishing media : High volume water jet
- Specific hazards during fire fighting : Do not allow run-off from fire fighting to enter drains or water courses.
- Hazardous combustion products : Carbon oxides  
Hydrogen fluoride  
Sulfur oxides  
Nitrogen oxides (NOx)
- Further information : Collect contaminated fire extinguishing water separately. This must not be discharged into drains.  
Fire residues and contaminated fire extinguishing water must be disposed of in accordance with local regulations.
- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Avoid dust formation.  
Avoid breathing dust.  
Refer to protective measures listed in sections 7 and 8.
- Environmental precautions : Prevent product from entering drains.  
Prevent further leakage or spillage if safe to do so.  
If the product contaminates rivers and lakes or drains inform respective authorities.
- Methods and materials for : Keep in suitable, closed containers for disposal.

**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

containment and cleaning up

**SECTION 7. HANDLING AND STORAGE**

- Advice on protection against fire and explosion : Avoid dust formation.  
Provide appropriate exhaust ventilation at places where dust is formed.
- Advice on safe handling : Avoid formation of respirable particles.  
Do not breathe vapors/dust.  
Avoid exposure - obtain special instructions before use.  
Avoid contact with skin and eyes.  
For personal protection see section 8.  
Smoking, eating and drinking should be prohibited in the application area.  
Dispose of rinse water in accordance with local and national regulations.
- Conditions for safe storage : Keep container tightly closed in a dry and well-ventilated place.  
Containers which are opened must be carefully resealed and kept upright to prevent leakage.  
Electrical installations / working materials must comply with the technological safety standards.
- Storage temperature : Protect from heat and light
- Further information on storage stability : No decomposition if stored and applied as directed.
- Packaging material : Suitable material: Stainless steel, Polyethylene bag in metal drum, Blister packages

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Baloxavir Marboxil	1985606-14-1	IOEL	0.0025 mg/m3	Roche Industrial Hygiene Committee (RIHC)
Cellulose	9004-34-6	TWA	10 mg/m3	ACGIH
		TWA (Respirable)	5 mg/m3	NIOSH REL
		TWA (total)	10 mg/m3	NIOSH REL
		TWA (total dust)	15 mg/m3	OSHA Z-1
		TWA (respirable)	5 mg/m3	OSHA Z-1

# SAFETY DATA SHEET

## XOFLUZA Tablets 80 mg

Version  
1.0

Revision Date:  
06/15/2025

Date of last issue: -  
Date of first issue: 06/15/2025

		fraction)		
		TWA (Total dust)	15 mg/m3	OSHA P0
		TWA (respirable dust fraction)	5 mg/m3	OSHA P0
Titanium oxide (TiO2)	13463-67-7	TWA (total dust)	15 mg/m3	OSHA Z-1
		TWA (Total dust)	10 mg/m3	OSHA P0
		TWA (Respirable particulate matter)	0.2 mg/m3 (Titanium dioxide)	ACGIH
		TWA (Respirable particulate matter)	2.5 mg/m3 (Titanium dioxide)	ACGIH
Substance name		Environmental Compartment		Value
Baloxavir Marboxil		Surface waters		9.2 µg/l
		Remarks:Based on chronic data, Information refers to the main ingredient.		

### Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

### Hand protection

In case of contact through splashing:

Material : Nitrile rubber  
Break through time : > 30 min  
Glove thickness : > 0.11 mm

In case of full contact:

Material : butyl-rubber  
Break through time : > 480 min  
Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.

Eye protection : Eye wash bottle with pure water  
Tightly fitting safety goggles

**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

- Skin and body protection : Dust impervious protective suit  
Choose body protection according to the amount and concentration of the dangerous substance at the work place.
- Hygiene measures : When using do not eat or drink.  
When using do not smoke.  
Wash hands before breaks and at the end of workday.

---

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

- Appearance : tablet
- Color : white, light yellow
- Odor : Not applicable
- Odor Threshold : Not applicable
- pH : Not applicable
- Melting point/ range : No data available
- Boiling point/boiling range : No data available
- Flash point : Not applicable
- Evaporation rate : No data available
- Self-ignition : No data available
- Upper explosion limit / Upper flammability limit : No data available
- Lower explosion limit / Lower flammability limit : No data available
- Vapor pressure : No data available
- Relative vapor density : Not applicable
- Relative density : No data available
- Density : No data available
- Solubility(ies)  
Water solubility : No data available
- Solubility in other solvents : No data available

**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	Not applicable
Viscosity, kinematic	:	Not applicable
Explosive properties	:	No data available
Oxidizing properties	:	No data available
Particle characteristics		
Particle Size Distribution	:	No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	No dangerous reaction known under conditions of normal use.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	No decomposition if stored and applied as directed.
Conditions to avoid	:	No data available
Incompatible materials	:	No data available Not applicable
Hazardous decomposition products	:	No data available No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Acute toxicity**

Not classified due to lack of data.

**Product:**

Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
Acute inhalation toxicity	:	Acute toxicity estimate: 118.18 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: Calculation method
Acute dermal toxicity	:	Acute toxicity estimate: > 5,000 mg/kg

**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

Method: Calculation method

**Components:****Lactose-1-Hydrate:**

Acute oral toxicity : LD50 Oral (Rat): > 10,000 mg/kg  
Test substance: anhydrous substance

**Baloxavir Marboxil:**

Acute oral toxicity : LD50 Oral (Rat): > 2,000 mg/kg

**Cellulose:**

Acute oral toxicity : LD50 Oral (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 Dermal (Rabbit): > 2,000 mg/kg

**Titanium oxide (TiO<sub>2</sub>):**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Method: OECD Test Guideline 425

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

**Skin corrosion/irritation**

Not classified due to lack of data.

**Components:****Titanium oxide (TiO<sub>2</sub>):**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

**Serious eye damage/eye irritation**

Not classified due to lack of data.

**Components:****Titanium oxide (TiO<sub>2</sub>):**

Species : Rabbit  
Result : No eye irritation



**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

Method : OECD Test Guideline 405

**Respiratory or skin sensitization****Skin sensitization**

Not classified due to lack of data.

**Respiratory sensitization**

Not classified due to lack of data.

**Components:****Titanium oxide (TiO<sub>2</sub>):**

Species : Guinea pig  
Assessment : Does not cause skin sensitization.  
Method : OECD Test Guideline 406

**Germ cell mutagenicity**

Not classified due to lack of data.

**Components:****Baloxavir Marboxil:**

Genotoxicity in vitro : Method: Mutagenicity (Salmonella typhimurium - reverse mutation assay)  
Result: negative

Method: OECD Test Guideline 473  
Result: negative

Genotoxicity in vivo : Method: OECD Test Guideline 474  
Result: negative

**Carcinogenicity**

Suspected of causing cancer.

**Components:****Cellulose:**

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**Titanium oxide (TiO<sub>2</sub>):**

Carcinogenicity - Assessment : Limited evidence of a carcinogenic effect.

**IARC** Group 2B: Possibly carcinogenic to humans  
Titanium oxide (TiO<sub>2</sub>) 13463-67-7

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**

Not classified due to lack of data.

**Components:****Baloxavir Marboxil:**

Effects on fetal development : Species: Rat  
Application Route: Oral  
Dose: 1000 milligram per kilogram  
Duration of Single Treatment: 12 d  
Result: No effects on fetal development.

Species: Rabbit  
Application Route: Oral  
Dose: 100 milligram per kilogram  
Duration of Single Treatment: 12 d  
Result: No effects on fetal development.

**STOT-single exposure**

Not classified due to lack of data.

**STOT-repeated exposure**

Not classified due to lack of data.

**Repeated dose toxicity****Components:****Baloxavir Marboxil:**

Species : Rat  
NOAEL : 2000 mg/kg bw/day  
Application Route : Oral  
Exposure time : 2 Weeks  
Remarks : Subacute toxicity

**Aspiration toxicity**

Not classified due to lack of data.

**Further information****Product:**

Remarks : No data available

**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Lactose-1-Hydrate:****Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to  
the environment : No data available**Baloxavir Marboxil:**Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 10.6 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
GLP: yes  
Remarks: average measured concentrationNOEC (Danio rerio (zebra fish)): 10.6 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
GLP: yes  
Remarks: average measured concentrationToxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 17.4 mg/l  
aquatic invertebrates Exposure time: 48 h  
Method: OECD Test Guideline 202  
GLP: yes  
Remarks: measured initial concentrationNOEC (Daphnia magna (Water flea)): 17.4 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: measured initial concentrationToxicity to algae/aquatic : ErC50 (Desmodesmus subspicatus (green algae)): 9.28 mg/l  
plants Exposure time: 72 h  
Method: OECD Test Guideline 201  
GLP: yes  
Remarks: average measured concentrationNOErC (Desmodesmus subspicatus (green algae)): 1.75 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
GLP: yes  
Remarks: average measured concentration

EyC50 (Desmodesmus subspicatus (green algae)): 4.76 mg/l

**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

Exposure time: 72 h  
Method: OECD Test Guideline 201  
GLP: yes  
Remarks: average measured concentration

Toxicity to microorganisms : (activated sludge): Exposure time: 14 d  
Method: OECD Test Guideline 301F  
GLP: yes  
Remarks: no adverse influence on substrate biodegradation

**Cellulose:****Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

**Titanium oxide (TiO<sub>2</sub>):**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l  
Exposure time: 96 h  
Test Type: static test

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 10,000 mg/l  
Exposure time: 96 h  
Test Type: semi-static test  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : LC50 (Daphnia magna (Water flea)): > 1,000 mg/l  
Exposure time: 48 h  
Test Type: static test  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l  
Exposure time: 72 h  
Test Type: static test  
Method: OECD Test Guideline 201

EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l  
Exposure time: 72 h  
Method: ISO 10253

NOEC (Skeletonema costatum (marine diatom)): 5,600 mg/l  
Exposure time: 72 h  
Method: ISO 10253

**Ecotoxicology Assessment**

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025**Persistence and degradability****Components:****Lactose-1-Hydrate:**

Biodegradability : Remarks: No data available

**Baloxavir Marboxil:**Biodegradability : Result: Not readily biodegradable.  
Biodegradation: < 10 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301F  
GLP: yesPhysico-chemical : Method: OECD Test Guideline 301F  
removability : Remarks: Not abiotically degradable**Titanium oxide (TiO<sub>2</sub>):**

Biodegradability : Remarks: Not applicable

**Bioaccumulative potential****Components:****Lactose-1-Hydrate:**

Bioaccumulation : Remarks: No data available

Partition coefficient: n- : log Pow: -5.01  
octanol/water : Remarks: anhydrous substance**Baloxavir Marboxil:**Partition coefficient: n- : log Pow: 2.24  
octanol/water : Method: calculated, consensus of various QSARslog Pow: 2.46 (77 °F / 25 °C)  
pH: 5  
Method: OECD Test Guideline 117  
GLP: yeslog Pow: 2.45 (77 °F / 25 °C)  
pH: 7  
Method: OECD Test Guideline 117  
GLP: yeslog Pow: 2.46 (77 °F / 25 °C)  
pH: 9  
Method: OECD Test Guideline 117  
GLP: yes**Cellulose:**Partition coefficient: n- : Remarks: No data available  
octanol/water

**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025**Titanium oxide (TiO<sub>2</sub>):**Partition coefficient: n-  
octanol/water : Remarks: No data available**Mobility in soil**

No data available

**Other adverse effects****Product:**Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82  
Protection of Stratospheric Ozone - CAA Section 602 Class I  
Substances  
Remarks: This product neither contains, nor was  
manufactured with a Class I or Class II ODS as defined by the  
U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A +  
B).Additional ecological  
information : An environmental hazard cannot be excluded in the event of  
unprofessional handling or disposal.  
Harmful to aquatic life with long lasting effects.

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**Waste from residues : The product should not be allowed to enter drains, water  
courses or the soil.  
Do not contaminate ponds, waterways or ditches with  
chemical or used container.  
Send to a licensed waste management company.Contaminated packaging : Empty remaining contents.  
Dispose of as unused product.  
Do not re-use empty containers.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable

**Domestic regulation****49 CFR**

Not regulated as a dangerous good

# SAFETY DATA SHEET

## XOFLUZA Tablets 80 mg

Version  
1.0

Revision Date:  
06/15/2025

Date of last issue: -  
Date of first issue: 06/15/2025

### Special precautions for user

Remarks : Not dangerous goods in the meaning of ADR/RID, ADN, IMDG-Code, ICAO/IATA-DGR

## SECTION 15. REGULATORY INFORMATION

### CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

Components	CAS-No.	Component TPQ (lbs)
------------	---------	---------------------

**SARA 311/312 Hazards** : Carcinogenicity

### Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM Intermediate or Final VOC's (40 CFR 60.489).

### Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

### US State Regulations

#### Massachusetts Right To Know

Cellulose 9004-34-6

#### Pennsylvania Right To Know

Lactose-1-Hydrate 64044-51-5  
Baloxavir Marboxil 1985606-14-1  
Cellulose 9004-34-6  
Croscarmellose sodium 74811-65-7  
2-Pyrrolidinone, 1-ethenyl-, homopolymer 9003-39-8

**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025**Maine Chemicals of High Concern****Vermont Chemicals of High Concern****Washington Chemicals of High Concern****California Prop. 65**

WARNING: This product can expose you to chemicals including Titanium oxide (TiO<sub>2</sub>), which is/are known to the State of California to cause cancer. For more information go to [www.P65Warnings.ca.gov](http://www.P65Warnings.ca.gov).

**California List of Hazardous Substances**

2-Pyrrolidinone, 1-ethenyl-, homopolymer 9003-39-8

**California Permissible Exposure Limits for Chemical Contaminants**

Cellulose 9004-34-6

**The ingredients of this product are reported in the following inventories:**


AIIC	: Not in compliance with the inventory
DSL	: This product contains the following components that are not on the Canadian DSL nor NDSL.  Baloxavir Marboxil  Croscarmellose sodium  non hazardous compounds  sodium octadecyl fumarate
NZIoC	: Not in compliance with the inventory
ENCS	: Not in compliance with the inventory
ISHL	: Not in compliance with the inventory
KECI	: Not in compliance with the inventory
PICCS	: Not in compliance with the inventory
IECSC	: Not in compliance with the inventory
TCSI	: Not in compliance with the inventory
TSCA	: Product contains substance(s) not listed on TSCA inventory.
TECI	: Not in compliance with the inventory

**TSCA list**

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.



**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025**SECTION 16. OTHER INFORMATION****Further information****NFPA 704:****HMIS® IV:**

HEALTH	*	0
FLAMMABILITY		0
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	: USA. NIOSH Recommended Exposure Limits
OSHA P0	: USA. Table Z-1-A Limits for Air Contaminants (1989 vacated values)
OSHA Z-1	: USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	: 8-hour, time-weighted average
NIOSH REL / TWA	: Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA P0 / TWA	: 8-hour time weighted average
OSHA Z-1 / TWA	: 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test

**XOFLUZA Tablets 80 mg**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 06/15/2025

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN / 2404